Full formMedical & Health
EUAstands forEmergency Use Authorization
Full Form of EUA
What is EUA?
Emergency Use Authorization (EUA) is a regulatory mechanism that allows the use of unapproved medical products—such as vaccines, diagnostics, and therapeutics—during public health emergencies when no adequate, approved alternatives are available. In India, the Central Drugs Standard Control Organization (CDSCO), under the Drugs Controller General of India (DCGI), grants EUAs to expedite access to critical interventions while ensuring safety and efficacy through a streamlined review process. This framework became particularly prominent during the COVID-19 pandemic, when Indian pharmaceutical companies like Bharat Biotech and Serum Institute of India received EUAs for vaccines such as Covaxin and Covishield. EUAs are time-bound, subject to post-authorization monitoring, and can be revoked if safety concerns arise. They are used not only for vaccines but also for repurposed drugs like remdesivir and rapid antigen test kits. In exams like the UPSC and NEET, EUA is often discussed in the context of public health policy, regulatory science, and pandemic response. Understanding EUA helps students grasp how India balances urgency with safety in healthcare emergencies.
EUA का फुल फॉर्म
आपातकालीन उपयोग प्राधिकरण
Example
The Drugs Controller General of India granted an Emergency Use Authorization to Covaxin in January 2021, allowing its rollout in the national vaccination drive.
EUA — frequently asked questions
What is the full form of EUA?
The full form of EUA is Emergency Use Authorization. It is a regulatory pathway that allows the use of unauthorized medical products during public health emergencies.
Who grants Emergency Use Authorization in India?
In India, the Drugs Controller General of India (DCGI) under the Central Drugs Standard Control Organization (CDSCO) grants Emergency Use Authorizations for vaccines, drugs, and diagnostics.
Is EUA the same as full approval?
No, EUA is a temporary authorization granted during emergencies, subject to ongoing safety monitoring and periodic review. Full approval requires more extensive clinical data and a longer review process.